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It is widely believed that perinatal cardiomyocyte
terminal differentiation blocks cytokinesis, thereby
causing binucleation and limiting regenerative repair
after injury. This suggests that heart growth should
occur entirely by cardiomyocyte hypertrophy during
preadolescence when, in mice, cardiac mass in-
creases many-fold over a few weeks. Here, we
show that a thyroid hormone surge activates the
IGF-1/IGF-1-R/Akt pathway on postnatal day 15
and initiates a brief but intense proliferative burst of
predominantly binuclear cardiomyocytes. This prolif-
eration increases cardiomyocyte numbers by40%,
causing a major disparity between heart and cardio-
myocyte growth. Also, the response to cardiac injury
at postnatal day 15 is intermediate between that
observed at postnatal days 2 and 21, further sug-
gesting persistence of cardiomyocyte proliferative
capacity beyond the perinatal period. If replicated
in humans, this may allow novel regenerative thera-
pies for heart diseases.
INTRODUCTION
The regulation of heart size during postnatal development is a
fundamental process directly relevant to remodeling of the heart
in response to congenital heart diseases. Postnatal change in the
size of the mammalian heart through replication of cardiac mus-
cle cells (cardiomyocytes [CMs]) is thought to be limited by early
postnatal terminal differentiation (Soonpaa et al., 1996; Walsh
et al., 2010). This notion was proposed as early as 1894 by Biz-
zozero, who suggested that replication of CMs ceases at birthand classified mature CMs as elementi perenni, or cells of static
populations.
The view that CMs terminally differentiate in the neonatal
period (by postnatal day 5 [P5]) is supported by evidence that
during early preadolescence (from P5 to P14), the expression
of genes responsible for cell-cycle reentry, mitosis, and cyto-
kinesis falls precipitously (Walsh et al., 2010). This change is pre-
ceded between P5 and P10 by extensive binucleation of CMs
(Soonpaa et al., 1996; Walsh et al., 2010), widely considered a
marker of terminal differentiation; by P7, hearts lose regenerative
capacity (Porrello et al., 2011). Between P10 and P21 (weaning),
estimates of S phase indicate that CMs are quiescent (Soonpaa
et al., 1996). Assessments of mitosis in murine CMs at select
ages (Walsh et al., 2010) also support the conclusion that repli-
cation ceases by P5–P7.
Inmammals, the heart growsmarkedly between the immediate
postneonatal period and puberty. If CMs are terminally differen-
tiated, this growth should be due almost entirely to an increase in
the volume of constituent CMs, which throughout postneonatal
life account for 80% of the volume of the myocardium (Li et al.,
1996). In humans, a disparity between changes in CM volume
and heart volume is readily observed between birth and 20 years
(Mollova et al., 2013). This disparity suggests a 3.4-fold increase
in the CM population number (CPN). Senyo et al. (2013) have
investigated the source of such new CMs in the mouse, the
only species in which the timing of terminal differentiation has
been evaluated. They report that CMs are added to postneonatal
hearts at a rate of 0.76% per year and that these new cells are
derived from a small fraction (<0.2%) of mononuclear CMs that
retain proliferative capacity. This rate of CM addition predicts
only a negligible (1.06-fold) increase in CPN between the onset
of terminal differentiation (around P5) and puberty (P35).
Here, we show a 1.4-fold increase in CPN during the preado-
lescent period, which occurs as a discrete proliferative burst on
P15 initiated by a surge in thyroid hormone (T3). Proliferation isCell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc. 795
Figure 1. Rapid Body Growth Involves CM Elongation and Eccentric LV Remodeling
(A and B) Concomitant increases in body and heart weights of wild-type (WT) mice during the period from preadolescence (P10) to just after puberty (P35).
(C) Increase in heart size from P10 to P35 is illustrated by hematoxylin and eosin-stained coronal heart sections.
(D–L) Hemodynamic and cardiac and CM morphological changes in WT mice from P10 to P35. LVEDD and LVED volume indicate left ventricular end-diastolic
dimension and volume, respectively; LV FWd, LV free wall thickness in diastole.
Data are shown as mean ± SEM. The number of animals, or cells, studied is shown by n. ***p < 0.001.evident from an increase in CPN, the re-expression of mitosis-
related genes, readily apparent mitotic figures in mature mono-
and binuclear CMs and, consistent with cell division giving rise
to smaller progeny, a sharp fall in both mono- and binuclear
CM volume. The brevity of this proliferative burst could explain
why it has previously gone undetected. This study provides
compelling evidence for retention of CM proliferative compe-
tence long after the neonatal period, which requires a significant
revision of the generally accepted view of CM terminal
differentiation.796 Cell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc.RESULTS
Disparity between Heart and CM Growth during
Postnatal Development
Between early preadolescence (P10) and puberty (P35),
mouse body weight nearly doubles each week (Figure 1A).
Assuming that circulatory volume increases in direct proportion
to body weight, circulatory volume should increase by 15%
each day, with equivalent increases in heart weight (Figures 1B
and 1C). Echocardiography shows that between P10 and P35,
Figure 2. A Period of CM Proliferation dur-
ing Preadolescent Heart Growth
(A) Total numbers of cardiomyocytes in both
cardiac ventricles of mice (CM population number
[CPN]). The number of animals studied is shown in
square brackets.
(B–G) Enhanced expression of the mitosis-related
genes Ki67, Cyclin B1, polo-like kinase-1 (Plk 1),
aurora A, Survivin, and anillin on P15. Also note
suppressed expression of all these genes in P35
hearts (p < 0.001 versus P13 values). Values were
determined using RNA prepared from five animals
at each time point.
(H–J) An example of flow cytometric analysis of
BrdU+/cardiac troponin T+ (cTnT+) CM-derived
nuclei obtained from a mouse given a single
intraperitoneal injection of BrdU on the night of
P14 and then sacrificed on P18.
(K) A representative example of analysis of BrdU
uptake (at P14 evening) and ploidy, indicating that
96.4% of nuclei were 2n and 3.6% were 4n (on
P18) in this cell preparation from a single heart.
Data are shown as mean ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001.stroke volume increases 3.5-fold (p < 0.001) (Figure 1D). This is
associated with left ventricle (LV) chamber remodeling, giving
an 86% increase in LV end-diastolic dimension (LVEDD) (p <
0.001; Figure 1E) and a 4.6-fold increase in LV volume at diastole
(p < 0.001; Figure 1F), without a significant change in LV free wall
thickness at diastole (FWd or h) (Figure 1G). This adaptation
produces a 52% decrease in the LV h/Ri ratio (where Ri is the in-
ternal LV chamber radius; Figure 1H), consistent with eccentric
hypertrophy, andmaintains the LVweight-to-stroke volume ratio
(1.76:1 at P10 versus 1.78:1 at P35). Also between P10 and P35,
the LVEDD length-to-diameter ratio decreases by 40% (p <Cell 157, 7950.001; Figure 1I), indicating increased LV
sphericity. At the cellular level, CM length
increases by 46 mm (p < 0.001; Figure 1K)
between P10 and P35, with minimal
(+1 mm) change in diameter (p < 0.001;
Figure 1L).
The increase in ventricular weight be-
tween P10 and P35 (21.7 ± 1.43 mg, n =
9 at P10 versus 75.3 ± 5.56 mg, n = 5 at
P35; +3.47-fold; p < 0.001) exceeds the
increase in ventricular CM volume by
1.7-fold, calculated on the basis of a
cylindrical model (18.2 ± 0.31 pl, n = 511
at P10 versus 36.3 ± 0.78 pl, n =
497; +1.99-fold; p < 0.001). This disparity
between increases in heart and CM
volume suggested an increase in CM
numbers during preadolescence.
Extensive CM Proliferation in the
Preadolescent Heart
We determined total CM numbers in
ventricular myocardium by enzymaticdisaggregation and direct cell counting. Estimates of total CM
numbers (summarized in Figure 2A) identify two distinct in-
creases in CPN: an 40% increase between P1 and P4, and
a further 40% increase (500,000 CMs) between P14
and P18. A total of 22% of the post-P14 CPN increase occurred
by 4:00 p.m. on P15 (P15 afternoon or P15A; p < 0.001;
Figure 2A), with no further change between P18 and P365.
Because variable CM yields among mice of different ages might
confound our count, we calculated the CM fraction ofmyocardial
volume-to-CM volume ratio, a yield-independent method for
estimating CM numbers (Chaudhry et al., 2004), and found–807, May 8, 2014 ª2014 Elsevier Inc. 797
1.26 ± 0.03 3 106 CMs in both ventricles at P14 (n = 10) versus
2.2 ± 0.06 3 106 at P18 (n = 5) (p < 0.001). Thus, both a hemo-
cytometer-based method and a yield-independent method
show a large increase in CM numbers between P14 and P18.
The latter method, because it requires several assumptions,
likely overestimates the increase. Collectively, these data indi-
cate that the preadolescent increase in CPN results from a
discrete CM proliferative burst at P15, rather than continuous
low-level CM addition.
To determine the time of onset of mitosis, we measured the
expression of several mitosis-promoting genes in the cardiac
ventricles daily from P13 to P16 (Figures 2B–2G). We found
5- to 12-fold increases in mRNA levels (p < 0.05) of all these
genes on the morning (9:00 a.m.) of P15, with levels on P16
falling to near-P13 levels. Thus, CMs are in M phase as early
as 9:00 a.m. on P15. Assuming that the combined duration of
S and G2 phases is 10 hr (for a 24 hr cell cycle), S phase could
start around 10:00 p.m. on P14. To identify S phase timing, we
gave a single intraperitoneal injection of bromodeoxyuridine
(BrdU) (bloodstream half-life 2 hr; Kriss and Revesz, 1962) at
9:30 p.m. on the night of P14. Mice were sacrificed on P18
and CMs isolated and purified to remove non-CMs; their nuclei
were then liberated by lysis and analyzed by flow cytometry
(an example is shown in Figures 2H–2J). More than 99%of nuclei
from CM-enriched cardiac cells were cTnT positive, arguing
against significant contamination by non-CM nuclei. Flow
cytometry further indicated that 11.3% ± 1.9% (n = 6) of CM-
derived (cardiac troponin T [cTnT]-positive) nuclei were BrdU
positive (e.g., Figure 2J). BrdU’s short half-life in the circulation
makes it unlikely that all CMs entering S phase on the night of
P14 would be labeled by a single intraperitoneal BrdU pulse,
but cell/nuclear divisions during the 3-day chase period would
increase the number of BrdU-labeled nuclei. Thus, while our
findings do not establish the number of nuclei entering S phase
on the night of P14, they do show that a new S phase in CMs be-
gins late on P14.
The long chase period also determined that the BrdU-labeled
nuclei underwent nuclear division after labeling on the evening of
P14. By the end of the chase period, the majority of the BrdU-
labeled CMnuclei were 2n (96.4% ± 0.48%were BrdU+ 2n nuclei
and 3.6% ± 0.5%were BrdU+ 4n nuclei; n = 5/group) (Figure 2K).
Moreover, despite this post-P14 DNA synthesis in CMs, ploidy
was not increased between P14 and P18 (Figure S1 available on-
line). Together, these findings indicate efficient karyokinesis.
We next identified mitotic CMs by monitoring coexpression of
aurora B and the sarcomeric marker protein a-cardiac muscle
actin (SaA) by confocal microscopy. The subcellular localization
of aurora B is dependent on cell-cycle phase, so it can be used to
distinguish between potential outcomes of progression into M
phase (Carmena and Earnshaw, 2003). Transverse sections of
ventricles of mice sacrificed between 8:00 a.m. and 12:00 p.m.
revealed a 36-fold increase in LV CM mitoses between P14
and P15 (p < 0.001) followed by an abrupt 5.8-fold decrease
between P15 and P16 (p < 0.001) (Figures 3A–3E). These
changes paralleled changes in expression of mitosis-promoting
genes (Figures 2B–2G). Nuclear localization of aurora B in most
of the mitotic CMs indicated that these cells were in prophase
(Figure 3B).798 Cell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc.Mitotic CM nuclei were not uniformly distributed throughout
the LV wall, being 2.6-fold more abundant in subendocardial
than in subepicardial myofibers of the P15 LV (p < 0.01; Figures
3B and 3F). In these transverse cross sections, CMs in the sub-
endocardium are cut along their short axes, while CMs in the
subepicardium are cut along their long axes; these latter myofib-
ers are oriented circumferentially in the LV wall (Figure 3B).
We also found that 14.5% ± 2.6% of LV CM nuclei were in
mitosis versus 0.73% ± 0.4% in the right ventricle (RV) (Figure 3E)
(n = 5/group; p < 0.001). Figures S2A–S2C illustrate this differen-
tial distribution of mitotic CMs in a transverse section of P15
heart, which is in contrast to the broad distribution of mitotic
CMs in P2 neonatal heart (Figures S3A–S3C).
To verify the abundance of mitotic CMs in P15 cardiac ventri-
cles, we purified CMs after enzymatic disaggregation, and used
a-sarcomeric myosin heavy chain (a-MHC) and aurora B immu-
nofluorescence to identify CMs in M phase. Approximately 10%
of total mitotic P15 CMs were mononuclear (had an aurora
B-positive nucleus or aurora B localized at the anaphase spindle
midzone), and90% were binuclear (aurora B-positive nuclei or
aurora B localized at the anaphase spindle midzone of 2 pairs of
nuclei) (Figure 3G). A total of 34.2% ± 4.4% and 30.8% ± 2.7% of
mono- and binuclear CMs, respectively, were in M phase (n = 6)
(Figure 3H); this is 2-fold higher than in immunohistochemical
analyses (Figure 3E), which have been shown to underestimate
mitoses (Mollova et al., 2013).
In some mitotic binuclear CMs, we found sarcomeric struc-
tures on the periphery (e.g., Figure 3G shows a binucleate CM
in anaphase, labeled ‘‘A’’). Localized disruption of sarcomeres
may facilitate chromosomemovement and cytokinesis but could
also adversely affect LV function. However, cardiac contractility
was similar in P14 and P15 hearts (LV fractional shortening:
35.8% ± 3% in P14 hearts versus 35.1% ± 2.3% in P15A hearts;
n = 6/group; p = 0.87), suggesting that the sarcomeric disruption
noted in P15 CMs was not sufficient to depress LV function.
Cytokinesis requires the formation and constriction of a
mature contractile ring. Aurora B and the central spindlin com-
ponent mitotic kinesin-like protein (MKLP1) make independent
contributions to this process (Lewellyn et al., 2011). Because
most of the mitotic CMs in P15A hearts were in the LV sub-
endocardium (where myofibers are oriented longitudinally), we
examined CMMKLP1 localization in longitudinal sections, where
axial views of CMs in late mitosis are more likely. Approximately
4% of CMs contained MKLP1 between pairs of CM nuclei (Fig-
ures 3I and 3J). The frequency of these CM MKLP1+ events
and of mitotic figures (Figures S4A–S4E) supports CM prolifera-
tion in P15 hearts.
Modes of Mitosis in Mononuclear and Binuclear CMs
Mononuclear CMs that have entered M phase can produce two
mononuclear daughter cells via a conventional cell cycle. We
calculated the number of mono-, bi-, and multinuclear CMs
added to the ventricles between the morning of P14 (9:00 a.m.)
and the afternoon of P15 (4:00 p.m.) by multiplying the average
CPN (Figure 2A) by the percentages of CMs that were mono-
nucleate, binucleate, or multinucleate at these times (Figures
4A–4D; Table S1). The most striking change was the addition
of 11.5 3 104 mononuclear CMs (2.3-fold increase). For extant
Figure 3. The Proliferative Burst Is Tempo-
rally Discrete and Involves Division of Pre-
dominantly Subendocardial CMs
(A–D) Immunohistochemical identification of
mitotic CMs (red staining, aurora B+ nuclei in
a-sarcomeric actin+ CMs stained in green) in
transverse cut tissue sections showing localiza-
tion in the subendocardial regions of the left
ventricle (LV) of P15 mice, with few aurora B+ cells
evident in the subepicardial regions of the LV, in
the right ventricle (RV) or in LV sections of P14 or
P16 hearts. The nuclear localization of aurora B
indicates that these CMs are in prophase.
(E and F) Quantitation of aurora B+ cells identified
(A–D), as seen in various regions of the LV and RV
of P14, P15, and P16 hearts.
(G) Quantitation of LV aurora B+ P15-CMs showing
that 90% are binucleated. In the adjacent
photomicrograph, the punctate aurora B staining
(red) indicates that these CMs, labeled P, are in
prophase. In another CM, labeled A (anaphase),
aurora B localization between nuclei pairs is
consistent with its localization at centromeres
between kinetochores, or at the anaphase spindle
midzone (asm). Note also the loss of cross-stria-
tions and marginalization of sarcomeric structures
in the CM labeled ‘‘A’’; blue, DAPI; green, a-MHC.
(H) Approximately equal percentages of P15
mononuclear (1N) and binuclear (2N) CMs are
aurora B+.
(I) CMs in late telophase/cytokinesis in longitudinal
sections of the LV subendocardium, detected
using an MKLP1 antibody. Arrowheads indicate
XY and XZ reconstruction planes in the enlarged
insets.
(J) Frequency of MKLP-1+ CM-specific events in
transverse sections of the LV subendocardium.
Data are shown as mean ± SEM. The number of
animals studied is shown by n or by values in
square brackets. **p < 0.01; ***p < 0.001; gp.,
group. See also Figures S2, S3, and S4.
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Figure 4. Increase in CM Population
Number Involves Division of Mono- and
Binuclear CMs
(A–C) Percentage of mononuclear (mono-CM),
binuclear (bi-CM), and multinuclear (multi-CM)
CMs in the hearts of P14, the afternoon of P15
(P15A), and P18 mice.
(D) Number of CMs in cardiac ventricles of P14,
P15A, and P18 mice. Total numbers are shown in
the left panel and the numbers of mono-, bi-, and
multinuclear CMs in these hearts are shown in the
right panel (these data are from Figure 2A). We
calculated the number of mono-, bi-, and multi-
nuclear CMs that are added to the cardiac ven-
tricles by multiplying the average CPN (Figure 2A)
with the percentage of CMs that were mono-, bi-,
or multinuclear at these developmental ages
(shown in Figures 4A–4C). In (A)–(D), the number of
animals studied is shown by the value in square
brackets.
(E–H) Volume (E and F), width (G), and length (H) of
mono- and binuclear CMs in P14, P15A, and P18
mouse hearts. The volume of individual CMs is
represented by a red (mono-CM) or green (bi-CM)
dot and was from the hearts of five mice at each
time indicated (E and F). In (G) and (H), histograms
represent averagewidths or length of CMs (n = 69–
107 mono-CMs/group and n = 391–512 bi-CMs/
group) from five mice at each time indicated.
(I) Scheme illustrating potential modes of cell
cycling during maturational heart growth. Mono-
nuclear CMs undergo a conventional cell cycle to
replicate. Binuclear CMs remain static or undergo
cell division. This involves each of the two nuclei
undergoing karyokinesis, with cytokinesis taking
place between nuclei pairs. This generates two
mononuclear CMs at the two poles and a smaller
binuclear CM remains at the center. Overall, these
processes increase the number of mononuclear
CMs, without greatly changing the number of
binuclear CMs. However, between P14 and the
afternoon of P15 (P15A), mono- and binuclear CM
volume decreases because smaller daughter cells
are generated from larger preexisting CMs.
Data are shown as mean ± SEM. **p < 0.01; ***p <
0.001. See also Figure S1 and Table S1.mononuclear CMs to be the sole source of this addition, all
mononuclear CMs present at P14 (calculated to be 8.5 3 104
cells) would need to undergo mitosis on P15. However, the
rate of mitosis in mononuclear CMs on P15 was only34% (Fig-
ure 3H); this could account for at most 2.93 104 cells (or 25% of
the addition). Moreover, mitosis of mononuclear CMs does not
explain the origin of the 6 3 104 binuclear, and the 9.4 3 104
multinuclear, CMs added between P14 and P15A (Table S1).
Binuclear CMs are thought to be incapable of division,
because polyploidy is considered to indicate terminal differenti-
ation. However, Miyaoka et al. (2012) propose that binuclear
hepatocytes that have enteredM phase assemble all condensed
chromosomes from two nuclei and produce two mononuclear
daughter cells, so that a binuclear cell is ‘‘consumed’’ with the800 Cell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc.birth of two mononuclear cells. Our calculations do not support
this as the dominant mechanism, because binuclear CM
numbers increase by 6% (or 6 3 104 cells). Nonetheless, the
finding that 90% of all P15 mitotic CMs are binucleate (Fig-
ure 3G) suggests amajor role for polyploid cells in the CM hyper-
plastic burst. The initiation of M phase and karyokinesis at each
nucleus of a binuclear CM, followed by cytokinesis between
pairs of newly generated daughter nuclei, could yield two small
mononuclear cells at the poles, with a binuclear cell remaining
at the center. The two nuclear divisions would each contribute
one nucleus to the binuclear daughter cell. We refer to this as
the ‘‘2+1 cell cycle.’’ In vitro examples of a 2+1 cell cycle in a
binuclear CM have been observed (Engel et al., 2005). Alterna-
tively, mitotic binuclear CMs could undergo acytokinetic mitoses
to yield multinuclear CMs or not proceed beyond prophase (i.e.,
abortive mitosis).
We considered these possibilities because confocal immuno-
cytochemical studies with aurora B revealed many binuclear
CMs in prophase; others displayed dual karyokinesis with evi-
dence of a spindle midzone between the nuclei in each pair
(that is, postkaryokinesis) (e.g., Figure 3G, inset). If a significant
number of 2+1 cell cycles occur, then the volume of binuclear
cells should decrease precipitously between P14 and the after-
noon of P15. Consistent with this scenario, the average volumes
of bi- and mononuclear CMs decreased by 60% (p < 0.001) and
43% (p < 0.001) (Figures 4E–4H), respectively, despite an
10% increase in heart weight (from 35.6 ± 0.86 mg, n = 10 at
P14 to 39.1 ± 1.3 mg at P15, n = 11; p < 0.05). If all mitotic mono-
nuclear CMs at P15 undergo a conventional cell cycle to yield
two mononuclear daughter cells, we calculate that it would
require only 7.3% of the binuclear CMs to undergo an uncon-
ventional 2+1 cell cycle in order to achieve the observed increase
in total mononuclear CM numbers, including the 6 3 104 binu-
clear CMs that are added (presumably through subsequent
endocycles in some mononuclear cells) between P14 and
P15A. These concepts are schematically illustrated in Figure 4I.
While some of the 9.4 3 104 multinuclear CMs added between
P14 and P15 might be intermediates of the 2+1 cell cycle,
most are unlikely to divide further because their numbers
decrease by only 7% in the following 3 days (Figure 4D). The
finding that binuclear CM size (but not numbers) decreases
sharply (by 60%), as mononuclear CM numbers increase by
2.3-fold between P14 and P15, supports polyploid CM mitoses
followed by cell division as the major component of the CM pro-
liferative burst.
c-kit+ Cardiac Stem and Progenitor Cells in
Preadolescent Hearts
We next evaluated if CM progenitor cells (c-kit+ and Nkx-2.5+)
derived from c-kit+ resident stem cells—the most abundant
CM-forming stem cell in postnatal hearts (Linke et al., 2005)—
might contribute to the mononuclear CM pool. Flow cytometric
analysis of the non-CM fraction of P14 ventricles showed
209 ± 52 (n = 5) c-kit+/Nkx-2.5 small interstitial cells (which
include c-kit+ cardiac- and bone marrow-derived stem cells)
and 69 ± 29 (n = 5) c-kit+/Nkx-2.5+ CM progenitors. These
numbers are insufficient to account for the addition of
500,000 CMs between P14 and P18.
Thyroid Hormone Triggers Cardiac Growth and
Hyperplasia during Early Preadolescence
Despite a highly significant correlation (r2 = 0.93; p < 0.0001)
between heart and body weight between P2 and P84 (Figure S5),
from P11 to P18 heart weight increased more than body weight
(Figure S5). This suggests that the preadolescent increase in
heart growth cannot be accounted for by rapid circulatory
volume expansion (or body weight) alone.
Immediately after P10, the rate of heart growth exceeded that
of body growth (Figure 5A), resulting in a rapid 30% increase in
heart-to-body weight ratio between P10 and P17 (p < 0.001).
The initial phase of this increase, between P10 and P14, was
by eccentric hypertrophy. This involved not only a 1.56-fold in-crease in cardiac mass (p < 0.001; Figure 1B) but also increases
in LV chamber dimensions (1.24-fold increase in LVEDD; p <
0.001) and volume (2.8-fold increase; p < 0.001) (Table S2),
with more prominent increases in CM length than width (Figures
S6A–S6C) but without CM hyperplasia (Figure 2A). These
changes caused a 22%decrease in the h/Ri ratio (p < 0.05; Table
S2), indicating an increase in LV wall stress based on the law of
LaPlace. But ventricular a/b-MHC mRNA ratio also increased
5-fold (p < 0.01; Figure 5B) and a-MHC levels increased 2.5-
fold (p < 0.05; Figure 5C), while atrial natriuretic factor mRNA
levels (a marker of pathological hypertrophy) were not signifi-
cantly increased (Figure 5D).
This molecular andmorphological signature suggests a 3,30,5-
triiodo-L-thyronine (T3 or thyroid hormone)-mediated effect,
since neither physiological nor pathological cardiac hypertrophy
causes large increases in the a/b-MHCmRNA ratio (e.g., Perrino
et al., 2006), but T3 excess does (Haddad et al., 2008). Consis-
tent with this hypothesis, serum T3 levels increase 5.6-fold
between P10 and P12 (Figure 5E). To determine if T3 is neces-
sary for the post-P10 cardiac growth, we inhibited T3 biosyn-
thesis with propylthiouracil (PTU). PTU administration from P7
decreased serum T3 levels at P14 by 43% (p < 0.05) (Figure 5E),
prevented the increase in the a/b-MHC mRNA ratio (Figure 5B),
and reduced heart weight more than body weight, so that by
P14–P18, the heart-to-body weight ratios of PTU-treated mice
were not significantly different from P10 mice (Figure 5F). This
is consistent with a high level of circulating T3 regulating cardiac
growth during early preadolescence. The subsequent decrease
in heart-to-body weight ratio between P16 and P21 (Figure 5A)
was due to a reduced rate of heart growth (relative to the previ-
ous 5 days) (Figure 1B), during which body weight continued to
rise (Figure 1A), but not due to a reduction in serum T3, which re-
mained high between P12 and puberty (Figure 5E).
Hence, preadolescent growth is characterized by a bidirec-
tional disparity in heart and bodyweight changes—first, between
P10 and P16, when heart growth exceeds that of the body, and
subsequently between P16 and P21, when body growth ex-
ceeds that of the heart. Together, these findings suggest that
between P10 and P14, T3 critically modulates the mode
by which body weight/circulatory volume drives heart growth,
allowing a more rapid increase in heart size during early
preadolescence.
We next evaluated the role of T3 in CM hyperplasia. Blockade
of T3 biosynthesis abrogated the developmental increase in the
CPN by P18 (Figure 5G). Also, a 7-day exposure of cultured P14
CMs to T3 (70 nM) produced an 2-fold increase in DNA syn-
thesis (BrdU incorporation) (p < 0.05; Figure 5H).
We then explored a potential link between T3 and insulin-like
growth factor-1 (IGF-1) in preadolescent hearts. The IGF-1-R/
Akt pathway in the heart is both prosurvival and proproliferative
(Dai and Kloner, 2011); IGF-1 is mainly secreted by cardiac
fibroblasts (Horio et al., 2005). Akt is required for phy-
siological growth in response to IGF-1 stimulation (DeBosch
et al., 2006). T3 regulates IGF-1 mRNA in osteoblasts via an
Igf1 thyroid hormone response element (TRE) (Xing et al.,
2012). IGF-1 causes fetal heart CM proliferation by activating
the IGF-1-R/PI3K/Akt pathway (Sundgren et al., 2003), and
postnatal CM numbers are increased in transgenic mice withCell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc. 801
Figure 5. Disparity in the Relationship
between Heart and Body Growth with CM
Proliferation Requires a T3 Surge
(A) Temporal change in heart-to-body weight
ratios of wild-type (WT) mice showing that heart
growth exceeds body growth between P10
and P18.
(B and C) Increase in LV a/b-MHC mRNA ratio (B)
and a-MHC expression (western blot above;
quantitation below) (C) from P10 and P14, and
blockade of the increase inmRNA ratio by PTU (B).
(D) Expression of ANP mRNA is not significantly
changed between P10 and P14.
(E) 3,30,5-Triiodo-L-thyronine (T3) levels increase
markedly between P10 and P12 and remain stable
thereafter. The increase in T3 is abrogated by PTU
(red dot and green bar).
(F and G) Increase in heart-to-body weight ratio
from P10 to P14, P15, and P18, and inhibition of
these increases by PTU (F). PTU also prevents the
increase in CPN between P10 and P18 (G).
(H) Treatment of cultured cardiomyocytes isolated
from P14 mice with T3 for 7 days increased the
percentage of BrdU+ CMs (cTnT+).
Data shown are the means ± SEM. The number of
individual animals studied is shown by n. *p < 0.05;
**p < 0.01; ***p < 0.001. See Figures S5, S6, and S7
and Table S2.cardiac-restricted IGF-1 overexpression (Reiss et al., 1996). We
found that IGF-1 mRNA and IGF-1 expression are increased
2.3-fold (p < 0.05; Figure 6A) and 39-fold (p < 0.05; Figures
6B–6F), respectively, in P15 relative to P10 hearts. Activation
of IGF-1-R requires phosphorylation that activates phosphati-
dylinositol-3 kinase (PI3K), which phosphorylates and activates
Akt. PTU suppressed both phospho-Tyr1161-IGF-1-R/glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) (Figure 6G and
6H) and phospho-Ser473-Akt/total Akt levels (Figure 6I), indi-
cating the involvement of T3 in activating the IGF-1-R/Akt
pathway in P15 ventricles.
Akt phosphorylates multiple substrates implicated in cell
survival and heart growth. In CMs, nuclear localization of Akt is
functionally important. Expression of constitutively activated
Akt results in CM hypertrophy (Condorelli et al., 2002), but
nuclear overexpression increases CM numbers (Rota et al.,
2005). Akt was mostly localized to CM nuclei in P15 hearts (Fig-
ures 6J–6N); in P10 hearts, its localization was cytoplasmic.
Consistent with the distribution of mitotic CMs (Figures 3E and
3F), Akt+ CM nuclei were predominantly in the subendocardium
of the P15 LV wall (Figure 6N) and were not detected in the RV.802 Cell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc.Collectively, these findings support a
role for T3 in triggering the P15 CM hy-
perplastic burst.
Cardiac Function after Myocardial
Infarction in Neonatal and Early
Postnatal Hearts
Extensive cardiac regeneration after
injury, leading to restoration of the ven-tricular wall without scar formation, is observed in P1, but not
P7 or P14, mice (Porrello et al., 2011, 2013). This is consistent
with the prevailing view that CMs permanently exit the cell cycle
by the end of the neonatal period (at P5). However, prominent
CM proliferation at P15, as shown above, might allow cardiac
regeneration. We thus evaluated the early regenerative potential
of P15 mouse hearts by subjecting them to myocardial infarction
and comparing their response to those of P2 and P21 animals.
Figure 7A shows examples of P2- and P15-injured hearts at 7
or 21 days postinfarction (dpi). Despite no significant differences
in infarct sizes at 1 dpi (Figure 7B), P21 infarct sizes were 6.8-fold
greater (p < 0.001) at 7 dpi than P2 infarct sizes, while infarct size
was intermediate in P15 hearts; infarct size was also 2.4-fold
greater (p < 0.01) at 7 dpi in P21 versus P15 hearts (Figure 7B).
We next compared levels of DNA synthesis in CMs within the
remote (nonischemic) and border zones, as compared to control
regions in age-matched sham-operated mice. We gave BrdU
intraperitoneally at 1 and 3 dpi and determined the number of
BrdU+ CMs in LVmyocardium at 7 dpi by immunohistochemistry
and confocal microscopy. There was robust cell-cycle activity
throughout the LV myocardium in both sham-operated and
Figure 6. Increased Expression of IGF-1
mRNA and IGF-1 in P15 Ventricles Causes
IGF-1-R and Akt Phosphorylation that Is
Inhibited by PTU
(A–F) Ventricular IGF-1 mRNA levels and IGF-1
immunostaining (IGF-1, red staining; DAPI, blue
staining; B–E, quantitation in F) at P10, P14, P15,
and P16, showing significant increases from P10
to a peak at P15.
(G–I) Immunoblotting (G) of ventricular myo-
cardium obtained from P10 and P15 mice, and
quantitation showing significant increases in the
P-IGF-1-R-to-GAPDH (H), and P-Akt-to-total Akt
ratios (I) between P10 and P15 and suppression of
these increases at P15 by PTU treatment. How-
ever, total Akt/GAPDH levels did not significantly
change at P15 after PTU treatment (I).
(J and K) Cytosolic Akt localization in P10 LV
sections (red) (J). In the presence of a-MHC
staining (green), the cytoplasm appears yellow
due to colocalization of Akt with a-MHC (K).
(L and M) Nuclear Akt localization in P15 LV
sections is evident from the purple staining (white
arrows), which results from the colocalization of
Akt (red) with DAPI (blue), and is also shown in the
adjacent magnified panel (L); nuclear localization
of Akt (indicated by purple staining and white
arrows) does not change the color of cytoplasmi-
cally localized a-MHC (green) (M).
(N) Quantitation of Akt+ CM nuclei shows few if
any cells in P10 right ventricle (RV), in the endo-
cardium (Endo) and epicardium (Epi) of P10 LV,
and in P15 RV. In P15 LV, Akt+ CM nuclei are
readily identified but are 51-fold more abundant in
endo- versus epicardium. n = 3–7 animals for each
individual evaluation.
Data shown are the means ± SEM. In all studies,
*p < 0.05; ***p < 0.001. See Figure S7.infarcted P2 hearts but10-fold lower levels of cell-cycle activity
in the border zone of P15 mice (versus that in injured P2 hearts;
p < 0.05) (Figure 7C). BrdU+ CMs were virtually undetectable in
the border zone of infarcted P21 hearts (Figure 7B). The detri-
mental impact of infarction on LV function (LV fractional short-
ening and ejection fraction; Figures 7D and 7E, respectively)
and LV wall thinning (Figure 7F) was not evident in P2 hearts at
7 dpi, as may be expected with extensive regenerative repair
(Figures 7A and 6C); it was intermediate at P15 and severe at
P21 (Figures 7D and 7E). These differences in functional and
morphological outcomes at 7 dpi in P2 and P15 mice were
independent of the size of the initial infarct (Figure 7B). Thus, in
murine hearts, the capacity for cardiac regeneration after P15
is intermediate between that at P2 and at P21.
DISCUSSION
Although CM terminal differentiation has been extensively
studied, when it occurs and what role it plays in early postnatal
heart maturation are fundamental questions that remain largely
unanswered. Here, we show that over a precisely timed interval
during the third week of life, 500,000 CMs are added to the
preadolescent mouse heart. This represents an 40% increasein CPN, with CM numbers remaining static thereafter. These new
cells are derived from CMs previously believed to have lost,
shortly after birth, their capacity to divide. Further, we find
evidence that thyroid hormone triggers the hyperplastic burst
at P15. Hence, it is likely that terminal differentiation in CMs
does not occur before P15: these findings question the 100-
year-old concept that CMs terminally differentiate in the neonatal
period (Bizzozero, 1894).
The Timing of CM Terminal Differentiation in Postnatal
Murine Hearts
Terminal differentiation in mature mammalian CMs means that
these cells have permanently withdrawn from the cell cycle.
Mechanisms responsible might include a marked suppression
of basal levels of expression of cell-cycle genes that promote
cell division and/or increased expression of genes that inhibit
the cell cycle (Poolman andBrooks, 1998).When CMs are forced
to reenter the cell cycle, as with forced overexpression of S
phase cyclins, endoreplicative cell cycles (or endocycles) pro-
duce large polyploid cells (Soonpaa et al., 1997). Alternatively,
cells that proceed past theG2/M phase checkpoint undergo acy-
tokinetic mitoses to generate large multinucleate cells (Soonpaa
et al., 1997). However, despite prominent cell-cycle checkpointsCell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc. 803
Figure 7. Reparative Response of P2, P15,
and P21 Hearts to Myocardial Infarction
(A) Representative coronal sections of hearts from
P2 and P15 mice at 7 and 21 days postmyocardial
infarction (MI; dpi) induced by left anterior de-
scending coronary artery ligation. Sections are
stained with picrosirius red to delineate scar tissue
(arrows) and fast green to delineate viable
myocardium. Note the virtual absence of scar
tissue in P2 MI mice at 7 and 21 dpi compared to
mice whose MI occurred at P15.
(B) Percent infarct size relative to the LV of P2,
P15, and P21 mice 1 and 7 dpi determined from
2,3,5-triphenyltetrazolium chloride and picrosirius
red with fast green-stained sections, respectively.
Note the differences in infarct sizes at 7 dpi despite
similar infarct sizes at 1 dpi.
(C) BrdU+/a-MHC+ CMs in the remote (non-
ischemic) and border zones of P2, P15, and P21
hearts at 7 dpi, showing fewer cells with evidence
of DNA synthesis (BrdU incorporation) in P15
hearts compared to P2 hearts and the absence of
such cells in P21 hearts.
(D) LV fractional shortening (FS) of P2, P15, and
P21 hearts at 7 dpi or sham operation, determined
from B-mode echocardiographic views at the
midpapillary or apical (peri-infarct) levels. Note the
reduction in FS in P15 hearts and themoremarked
reduction in FS in P21 hearts.
(E) Echocardiographically determined LV ejection
fraction (EF) of P2, P15, and P21 hearts at 7 dpi or
sham operation. Consistent with the changes in
FS, note the significant reduction in EF in the P21
hearts.
(F) Echocardiographically determined LV wall
thickness of P2, P15, and P21 hearts at 7 dpi,
expressed as a ratio of wall thickness in the peri-
infarct or control regions to that at the midpapillary
level. Consistent with the reductions in FS and EF,
note the significant reduction in LV wall thickness
in the P21 hearts.
Data shown are the means ± SEM. In all studies,
n = 3–7 animals for each individual evaluation. *p <
0.05; **p < 0.01; ***p < 0.001; n.s., nonsignificant.that produce this phenotype, a small number of preexisting CMs
in adult hearts can undergo cell division, which over time may
replace cells lost by apoptosis (Senyo et al., 2013). These may
be a small subset of CMs that have retained replicative com-
petency, or they may reflect a stochastic equilibrium between
replicative competence and terminal differentiation that heavily
favors the latter. This has been taken to suggest that, as murine
CMs exit the neonatal period (immediately after P5), most un-
dergo an endocycle that produces binuclear cells, which are
considered a defining manifestation of terminal differentiation
(e.g., Walsh et al., 2010).
Here, we show that numerous CMs reenter the cell cycle on
the night of P14; this culminates in cell division during P15.
Several lines of evidence suggest that new CMs are derived
from preexisting CMs. First, aurora B labeling indicates that804 Cell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc.30% of both mono- and binuclear CMs are in mitosis on the
morning of P15, and MKLP1 expression in 4% of LV sub-
endocardial CMs indicates impending cytokinesis. MKLP1 plays
an essential role in midbody formation and completion of cyto-
kinesis (Zhu et al., 2005) and marks imminent cytokinesis.
Second, cell counting indicates that 2.6 3 105 CMs are added
to the cardiac ventricles between P14 and P15A. Third, consis-
tent with cell division giving rise to small progeny, the average
mono- and binuclear CM volume abruptly decreases by
40%–60% and, consistent with extensive cytokinesis, this is
associated with a loss of large mono- and binuclear CMs
observed in P14 ventricles. Fourth, addition of 500,000 CMs
to the cardiac ventricles between P14 and P18 occurs withminor
changes in polyploidy or acytokinetic mitosis (as assayed by
multinucleation). On the morning of P15, 90% of mitotic CMs
are binucleate and, based on nuclear localization of aurora B,
most appear to be in prophase. Those that are in anaphase
display localized disruption of sarcomeres around their nuclei
but no loss of contractile function (LV fractional shortening) dur-
ing the CM replicative burst. Finally, there is a prominent 1-day
increase in many mitosis-regulating genes in P15 heart. These
considerations indicate that murine CMs are not terminally differ-
entiated during early preadolescence and challenge the notion
that binuclear CMs cannot divide.
We suppose that the synchronized and temporally restricted
nature of the CM proliferative burst in P15 hearts has inhibited
its detection. Soonpaa et al. (1996) found near-negligible levels
of S phase in P10–P21 CMs using a 2 hr in vivo 3H-thymidine
labeling protocol. This approach could miss a short synchro-
nized proliferative burst in which S phase starts during the night
of P14 and ends before the morning of P15 (S phase duration in
CMs is not known, but it could last 4 hr in a 24 hr cell cycle). In
support of this notion, we found extensive nuclear localization of
aurora B, indicating that these CMs have just passed the G2/M
phase transit point by the morning of P15. Walsh et al. (2010)
studied CM mitosis in P14, but not P15, CMs. Relative to P15
hearts, we observed very low levels of CM mitoses in P14 or
P16 hearts.
Porrello et al. (2011) report that hearts retain significant cardiac
regenerative potential for a brief time after birth. The link between
regenerative potential and postnatal cell-cycle arrest, as as-
sessed by CM binucleation, was suggested to indicate a brief
neonatal ‘‘cardiac regenerative window’’ that closes before P7.
We show here that CMs are not terminally differentiated at P15.
To ask if regenerative repair is possible at P15, we assessed
recovery from myocardial infarction in neonatal and postnatal
hearts (P2, P15, and P21). Our findings indicate an intermediate
phenotype in hearts injured at P15 (ejection fraction unchanged
but with a 64% depression of fractional shortening at the peri-
infarct level) relative to those injured at P2, which showed a
high degree of repair after injury (ejection fraction unchanged
with no depression of fractional shortening at the peri-infarct
level). Hearts injured at P21 (ejection fraction reduced by 40%,
with90% depression of fractional shortening at the peri-infarct
level) showed no evidence of injury-induced CM cell-cycle
reentry. This intermediate cardiac pathology in P15-injured
hearts might be due to the level of CM proliferation: BrdU incor-
poration into CMs in the border zone was lower than that in P2-
injured hearts, possibly because CMs terminally differentiate
within the7dpi follow-upperiod.Upregulation of the T3-triggered
IGF-1/IGF-1 receptor (IGF-1R)/phospho-Akt axis at P15,which is
prosurvival (Dai and Kloner, 2011), may also have played a role in
attenuating cardiac pathology in P15- versus P21-injured hearts.
Finally, immune responses to injury influence cardiac regenera-
tion and functional outcomes (Xin et al., 2013), factors that
change profoundly as the neonate transitions into preadoles-
cence (Levy, 2007). These complexities would need elucidation
to enable efficient regenerative repair in preadolescent hearts.
Preadolescent Heart Growth Occurs via a Distinct Form
of Physiological Hypertrophy
It is axiomatic that the main purpose of heart growth during pre-
adolescence is to increase stroke volume and cardiac output toaccommodate a growth spurt that almost quadruples body
weight (and hence circulatory volume) of P10 mice in just
25 days. Our studies indicate that maturational heart growth,
while sharing similarities with other forms of cardiac hypertro-
phy, shows differences that suggest that it is a distinct form of
physiological hypertrophy.
Mechanistically, LV volume overload of mitral regurgitation
leads to fiber elongation, chamber enlargement, and eccentric
hypertrophy (Grossman et al., 1975). Moreover, an increase in
LV sphericity and a decrease in h/Ri ratio cause an increase in
LV end-diastolic wall stress. By contrast, increases in LV cham-
ber volume during endurance exercise are accommodated by
elliptical remodeling of the heart (Schiros et al., 2013). This limits
the increase in LVEDD and, hence, based on LaPlace’s law (T =
P 3 Ri/h, where T is the tension or wall stress and P is the pres-
sure difference across the LV wall), wall stress and myocardial
oxygen demand do not need to increase as much as with an
equivalent increase in LV volume due to spherical remodeling.
We find that LV chamber sphericity increases, and the h/Ri ratio
decreases (by 50%), during maturational heart growth. Thus,
LV wall stress must increase progressively during maturational
growth. Despite this, stroke volume increases, most likely due
to an increase in a-MHC expression and to CM proliferation.
Maturational heart growth thus combines CM proliferation with
an increase in a-MHC, which correlates directly with overall
cardiac performance (Krenz and Robbins, 2004), thus indicating
a distinct form of cardiac remodeling.
Hyperplastic Heart Growth of Preadolescence Involves
Hemodynamic-Endocrine Interplay
Weobserved that preadolescent CM hyperplasia was abrogated
by inhibition of T3 biosynthesis. Moreover, T3 promoted cell-
cycle reentry of cultured P14 CMs. While these findings are
consistent with T3 being both necessary and sufficient for the
preadolescent proliferative burst, the fact that the spike in T3
occurs well before proliferation begins, as well as the uneven
but nonrandom distribution of mitotic CMs within the LV wall,
suggests a greater level of complexity. T3 also causes CMs to
elongate (Pantos et al., 2007), which is expected to increase
LVEDD and hencewall stress.We showed that LVEDD increased
markedly between P10 and P14. During isovolumic LV contrac-
tion, wall stress is higher in subendocardial than in subepicardial
regions (Mirsky, 1973). And, as shown in fetal (Saiki et al., 1997)
and early neonatal CMs (Sedmera et al., 2003), wall stress
stimulates CM replication. Thus, we speculate that the preado-
lescent CM proliferative burst involves an orchestrated interplay
between a permissive increase in T3 level and a regional increase
in wall stress (Figure S7).
These unique features of maturational heart growth are likely
to be important for maintaining cardiac performance during a
critical period of body growth, which is unsupported by
maternal/placental nutrient and oxygen supply and involves
increasing circulatory pressures. Furthermore, the finding that
CM proliferative capacity is sustained well beyond the neonatal
period may have important clinical implications. For example,
congenital hypoplastic heart syndromes are often treated with
palliative surgery and eventually cardiac transplantation. If hu-
man CMs, like those of the mouse, continue to divide efficientlyCell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc. 805
during preadolescence, this may provide a basis for stimulating
cardiomyogenesis in young patients by the administration of T3.
Indeed, a therapeutic benefit of T3 in the postoperative period
has been reported in newborn children undergoing operations
for complex congenital heart diseases (Chowdhury et al., 2001).
EXPERIMENTAL PROCEDURES
Animals
To minimize size variation, only male mice (C57BL/6J) from litters of six to
seven were used, unless otherwise indicated. To avoid potential inaccuracies
in the timing of birth, only animals with confirmed birthdates were used. Ani-
mals were handled according to Emory University or Victor Chang Cardiac
Research Institute institutional animal care and use committee guidelines.
Echocardiography
Echocardiography was performed under 2% isoflurane anesthesia as
described previously (Li et al., 2008) (see Extended Experimental Procedures).
Ventricular Myocardial Wall Volume
Ventricular volumes were determined from ventricular weights and the known
specific gravity of muscle. See Extended Experimental Procedures for details.
Myocardial Infarction and Infarct Size Determination
Mice were anesthetized and subjected to left anterior descending artery liga-
tion via left thoracotomy. Infarct sizes were determined on triphenyl tetrazo-
lium chloride (1 dpi) or picrosirius red/fast green-stained (7 dpi) sections, using
Image J software (NIH) or scanning by PowerMosaic microscopy, respectively
(see Extended Experimental Procedures).
CM Isolation, Nucleation, Ploidy, and Dimension Analyses
CMs were isolated by Langendorff perfusion and distinguished from non-CMs
by cytoplasmic size and phase-contrast microscopy. Samples (20 ml; 150
CMs/aliquot) were loaded in the counting chamber with a wide-bore pipette
and counted in triplicate using a hemocytometer. After purification, CMs
were stained with 40,6-diamidino-2-phenylindole (DAPI) for nucleation counts,
which were plotted as percentage of counted CMs using procedures
described by us previously (Li et al., 2008). CM dimensions were measured
using NIS-Elements 3.0 software (Nikon) (see Extended Experimental
Procedures).
Immunofluorescence
CMs and hearts were fixed and subjected to immunocytochemical and immu-
nohistochemical evaluation, respectively, as described previously (Li et al.,
2008) (see Extended Experimental Procedures).
Quantitative RT-PCR and Western Blot Analyses
RNA prepared from snap frozen heart ventricles was subject to quantitative
RT-PCR using standard techniques (see Extended Experimental Procedures
for details). Proteins extracted from snap frozen hearts were fractionated by
SDS-PAGE and subjected to immunoblotting, as described elsewhere (Li
et al., 2008) (see Extended Experimental Procedures).
CM Culture and Cardiac Stem Cell Analyses
CMs isolated from P14 hearts were cultured and subjected to T3 and BrdU
treatment and cardiac stem cells determined by flow cytometer analysis after
staining for c-kit and Nkx2-5 as detailed in Extended Experimental
Procedures.
Serum T3 Measurement
Serum T3 levels were determined with a T3 ELISA kit (Alpha Diagnostic
International).
Statistics
Data are presented as the mean ± SEM. Statistical differences of continuous
variables were determined by ANOVA followed by post hoc Bonferroni or806 Cell 157, 795–807, May 8, 2014 ª2014 Elsevier Inc.Dunnett’s tests or by Student’s t test. GraphPad Prism software was used
for statistical analysis. p < 0.05 was considered significant.
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